University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial 9L-18-14


An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post–ET-MF) Who Have Failed Ruxolitinib

Type: Treatment
Phase: Phase II
Status: Open to Accrual
Treatments: Chemotherapy: Systemic
Randomized: Not Asked
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Casey O'Connell, M.D.
Other Trial Staff:  Simbiso Peresuh, Coordinator, John Lee, D.M., Suraj Chandwani, D.M., Madelyn Lefler, Coordinator, Anastasia Philabaum, Coordinator, Christine Duran, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.